Becton, Dickinson and Company (NYSE:BDX) to Post Q2 2024 Earnings of $2.94 Per Share, Zacks Research Forecasts

Becton, Dickinson and Company (NYSE:BDXFree Report) – Equities research analysts at Zacks Research decreased their Q2 2024 earnings per share estimates for shares of Becton, Dickinson and Company in a research report issued to clients and investors on Monday, February 12th. Zacks Research analyst D. Dey now forecasts that the medical instruments supplier will earn $2.94 per share for the quarter, down from their prior estimate of $2.98. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $12.95 per share. Zacks Research also issued estimates for Becton, Dickinson and Company’s Q3 2024 earnings at $3.43 EPS, Q4 2024 earnings at $3.83 EPS, Q1 2025 earnings at $2.77 EPS, Q2 2025 earnings at $3.40 EPS, Q3 2025 earnings at $3.67 EPS, Q4 2025 earnings at $4.27 EPS and Q1 2026 earnings at $3.05 EPS.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last released its earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.39 by $0.29. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The business had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.73 billion. During the same quarter in the previous year, the business earned $2.98 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 2.6% on a year-over-year basis.

A number of other equities analysts also recently weighed in on the stock. Morgan Stanley lowered their target price on shares of Becton, Dickinson and Company from $310.00 to $280.00 and set an “overweight” rating on the stock in a report on Monday, December 4th. Barclays upped their price target on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research report on Monday, February 5th. TheStreet lowered shares of Becton, Dickinson and Company from a “b” rating to a “c+” rating in a research report on Thursday, November 9th. Piper Sandler dropped their price target on shares of Becton, Dickinson and Company from $305.00 to $280.00 and set an “overweight” rating on the stock in a research report on Friday, November 10th. Finally, Raymond James upped their price target on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $279.17.

Check Out Our Latest Analysis on BDX

Becton, Dickinson and Company Trading Down 0.2 %

Shares of Becton, Dickinson and Company stock opened at $243.37 on Tuesday. The stock has a market cap of $70.31 billion, a P/E ratio of 57.67, a P/E/G ratio of 2.01 and a beta of 0.43. The company has a quick ratio of 0.64, a current ratio of 1.08 and a debt-to-equity ratio of 0.56. Becton, Dickinson and Company has a 12-month low of $228.62 and a 12-month high of $287.32. The business’s 50 day moving average is $238.80 and its 200-day moving average is $253.14.

Hedge Funds Weigh In On Becton, Dickinson and Company

Institutional investors and hedge funds have recently modified their holdings of the business. RVW Wealth LLC acquired a new position in shares of Becton, Dickinson and Company in the third quarter valued at about $52,000. Bfsg LLC grew its stake in Becton, Dickinson and Company by 4.4% during the second quarter. Bfsg LLC now owns 24,083 shares of the medical instruments supplier’s stock worth $6,358,000 after buying an additional 1,005 shares in the last quarter. M. Kulyk & Associates LLC grew its stake in Becton, Dickinson and Company by 5.1% during the third quarter. M. Kulyk & Associates LLC now owns 16,640 shares of the medical instruments supplier’s stock worth $4,302,000 after buying an additional 809 shares in the last quarter. Cornerstone Advisors LLC acquired a new stake in Becton, Dickinson and Company during the second quarter worth about $871,000. Finally, Impax Asset Management Group plc grew its stake in Becton, Dickinson and Company by 90.2% during the third quarter. Impax Asset Management Group plc now owns 797,861 shares of the medical instruments supplier’s stock worth $205,816,000 after buying an additional 378,414 shares in the last quarter. 86.72% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Richard Byrd sold 2,156 shares of the stock in a transaction dated Tuesday, November 28th. The shares were sold at an average price of $238.47, for a total value of $514,141.32. Following the transaction, the executive vice president now directly owns 4,120 shares of the company’s stock, valued at $982,496.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 29th. Stockholders of record on Friday, March 8th will be given a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.56%. The ex-dividend date of this dividend is Thursday, March 7th. Becton, Dickinson and Company’s payout ratio is presently 90.05%.

About Becton, Dickinson and Company

(Get Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Stories

Earnings History and Estimates for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.